Mabion S.A. (MAB.WA)
PLN 10.9
(-0.18%)
PLN 10.9
(-0.18%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 6.84 Million PLN | -19.28% |
| 2022 | 8.47 Million PLN | 0.38% |
| 2021 | 8.44 Million PLN | 41.32% |
| 2020 | 5.97 Million PLN | -32.14% |
| 2019 | 8.8 Million PLN | -14.49% |
| 2018 | 10.29 Million PLN | 43.85% |
| 2017 | 7.15 Million PLN | 69.16% |
| 2016 | 4.23 Million PLN | 35.68% |
| 2015 | 3.11 Million PLN | -93.16% |
| 2014 | 45.62 Million PLN | 325.51% |
| 2013 | 10.72 Million PLN | 9.57% |
| 2012 | 9.78 Million PLN | 19678.87% |
| 2011 | 49.47 Thousand PLN | 206.01% |
| 2010 | 16.16 Thousand PLN | 0.0% |
| 2009 | 16.16 Thousand PLN | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 8.86 Million PLN | 29.55% |
| 2024 Q3 | 8.42 Million PLN | 12.71% |
| 2024 Q2 | 7.47 Million PLN | -15.68% |
| 2023 Q4 | 6.84 Million PLN | -11.69% |
| 2023 Q3 | 7.74 Million PLN | 1.44% |
| 2023 FY | 6.84 Million PLN | -19.28% |
| 2023 Q1 | 8.2 Million PLN | -3.27% |
| 2023 Q2 | 7.63 Million PLN | -6.84% |
| 2022 FY | 8.47 Million PLN | 0.38% |
| 2022 Q4 | 8.47 Million PLN | 23.86% |
| 2022 Q3 | 6.84 Million PLN | -3.44% |
| 2022 Q2 | 7.08 Million PLN | -21.45% |
| 2022 Q1 | 9.02 Million PLN | 6.86% |
| 2021 Q4 | 8.44 Million PLN | -56.48% |
| 2021 Q3 | 19.4 Million PLN | 62.89% |
| 2021 Q2 | 11.91 Million PLN | 177.82% |
| 2021 FY | 8.44 Million PLN | 41.32% |
| 2021 Q1 | 4.28 Million PLN | -28.25% |
| 2020 Q1 | 7.85 Million PLN | -10.79% |
| 2020 FY | 5.97 Million PLN | -32.14% |
| 2020 Q2 | 6.06 Million PLN | -22.85% |
| 2020 Q3 | 6.06 Million PLN | 0.02% |
| 2020 Q4 | 5.97 Million PLN | -1.42% |
| 2019 Q3 | 7.86 Million PLN | -12.11% |
| 2019 Q4 | 8.8 Million PLN | 11.95% |
| 2019 Q2 | 8.95 Million PLN | -13.29% |
| 2019 Q1 | 10.32 Million PLN | 0.23% |
| 2019 FY | 8.8 Million PLN | -14.49% |
| 2018 Q3 | 9.57 Million PLN | -0.11% |
| 2018 FY | 10.29 Million PLN | 43.85% |
| 2018 Q4 | 10.29 Million PLN | 7.51% |
| 2018 Q2 | 9.59 Million PLN | 9.36% |
| 2018 Q1 | 8.76 Million PLN | 22.49% |
| 2017 FY | 7.15 Million PLN | 69.16% |
| 2017 Q1 | 6.22 Million PLN | 47.0% |
| 2017 Q2 | 7.5 Million PLN | 20.69% |
| 2017 Q3 | 8.72 Million PLN | 16.17% |
| 2017 Q4 | 7.15 Million PLN | -17.92% |
| 2016 FY | 4.23 Million PLN | 35.68% |
| 2016 Q2 | 3.11 Million PLN | 0.0% |
| 2016 Q3 | 3.11 Million PLN | 0.0% |
| 2016 Q4 | 4.23 Million PLN | 35.68% |
| 2016 Q1 | 3.11 Million PLN | 0.0% |
| 2015 FY | 3.11 Million PLN | -93.16% |
| 2015 Q4 | 3.11 Million PLN | 63.9% |
| 2015 Q3 | 1.9 Million PLN | -73.1% |
| 2015 Q2 | 7.07 Million PLN | 56.06% |
| 2015 Q1 | 4.53 Million PLN | -90.07% |
| 2014 FY | 45.62 Million PLN | 325.51% |
| 2014 Q4 | 45.62 Million PLN | 732.61% |
| 2014 Q2 | 3.12 Million PLN | 270.11% |
| 2014 Q1 | 843 Thousand PLN | -92.14% |
| 2014 Q3 | 5.48 Million PLN | 75.64% |
| 2013 Q1 | 99 Thousand PLN | -98.99% |
| 2013 Q2 | 78 Thousand PLN | -21.21% |
| 2013 Q3 | 77 Thousand PLN | -1.28% |
| 2013 Q4 | 10.72 Million PLN | 13825.97% |
| 2013 FY | 10.72 Million PLN | 9.57% |
| 2012 Q4 | 9.78 Million PLN | 20101.03% |
| 2012 FY | 9.78 Million PLN | 19678.87% |
| 2012 Q3 | 48.44 Thousand PLN | 0.0% |
| 2011 FY | 49.47 Thousand PLN | 206.01% |
| 2010 FY | 16.16 Thousand PLN | 0.0% |
| 2009 FY | 16.16 Thousand PLN | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Bioceltix S.A. | 8617.89 PLN | -79304.587% |
| BIOTON S.A. | 117.91 Million PLN | 94.197% |
| Captor Therapeutics Spolka Akcyjna | - PLN | -Infinity% |
| Molecure S.A. | - PLN | -Infinity% |
| NanoGroup S.A. | 63.37 Thousand PLN | -10697.122% |
| Pharmena S.A. | 445 Thousand PLN | -1437.753% |
| Poltreg S.A. | 415 Thousand PLN | -1548.916% |
| Pure Biologics Spólka Akcyjna | 17.56 Million PLN | 61.046% |
| Ryvu Therapeutics S.A. | 2.11 Million PLN | -223.088% |
| Synthaverse S.A. | 15.48 Million PLN | 55.806% |
| Urteste S.A. | 162 Thousand PLN | -4124.074% |